HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.
about
HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory DiseasesThe Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor EfficacyEpigenetic Strategies to Boost Cancer Immunotherapies.PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?Entinostat for the treatment of breast cancer.Marked for death: targeting epigenetic changes in cancer.Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacyIntegrated genomic analysis of recurrence-associated small non-coding RNAs in oesophageal cancer.An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.Immune checkpoints and their inhibition in cancer and infectious diseases.Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy.Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside.Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy?HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma.Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca2+ Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK.Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation.HDAC inhibitors enhance the immunotherapy response of melanoma cells.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.HDAC inhibition potentiates immunotherapy in triple negative breast cancer.A potent hydroxamic acid-based, small-molecule inhibitor A452 preferentially inhibits HDAC6 activity and induces cytotoxicity toward cancer cells irrespective of p53 status.Modulation of antitumor immunity with histone deacetylase inhibitors.Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.Association of histone deacetylase expression with histology and prognosis of ovarian cancer.Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma.SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells.Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway.Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints.Immune checkpoint therapy in liver cancer.DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.MGCD0103 induces apoptosis and simultaneously increases the expression of NF-κB and PD-L1 in classical Hodgkin's lymphomaCytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonistsEpigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell typesOptimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapyUpregulation of PD‑L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300‑mediated NF‑κB signaling
P2860
Q26739120-C1D02F0D-B4A2-45F4-BEE0-2DF73769A7E3Q28076473-23C20DAE-E904-4441-B4BB-B5F40AA10A9BQ33838340-3813673F-ACB2-4836-A2A0-981CB3496E32Q33839204-06B0CA0A-B72D-4DF8-878C-20D1077E1624Q37066925-00486C93-A0E4-4AEC-B4AC-929270C2B0E8Q38674317-F675C797-00EC-4FEB-8BBD-E51C0D4B5748Q38747872-9EBBB1A5-78A2-4FB0-9ECB-2C6E5815F779Q38749824-4848F41A-430D-4BE1-AA2D-03BBC339C0A1Q38752754-EE26E2D1-13DF-4B34-BE84-E66BEA44DC38Q38765451-3B5591F6-DD9A-4ACC-B769-CED9369256FDQ38838643-092C1810-B6E3-4E63-87FA-DDDC6AC45308Q38845026-323A5C75-26BE-4F85-95DD-A45C144C2018Q38988078-3859D342-7826-4485-A01F-458EC12D4AA5Q38993736-DACFEBC5-8ADA-479C-8B0F-82E641E77B5BQ39045550-1EE291E2-068A-4A95-82EB-68A45271BB8CQ41739174-D4CF97DB-99E6-4F32-8CBA-C4F6BAB2F321Q42248631-A0C3A7E0-A726-419C-8F70-5734F4F0CF19Q42363777-DDA13EB0-B68C-4A5B-ADE6-87461DF6C5F4Q45072959-22F6C175-765D-4122-9D3D-45A73DB9D0FCQ47120629-54316143-B9FB-40E7-897B-902BB2D495A5Q47136084-F500DBEC-847A-45D2-8618-EFEF10DAB3B7Q47417938-A72441F9-6AC1-4CC4-BD51-5E03F90E5145Q48522970-E509C477-6B15-4CBE-90C4-5D6C1A42938EQ48610578-5F2D823C-C279-44F6-BCBC-AFAEAF02495EQ49557954-0F53FA1D-3BFF-4C75-8EE0-793784007538Q49853764-92523DC9-B4BA-4CF9-8534-43C53106A654Q49874952-7FF39464-FF49-47FC-8F7F-8CB4556D4ABEQ50147664-19A89EEB-3F2D-4AA6-9004-450B8308E4AFQ51183547-B537E51B-A529-41B8-BF10-10A7052A578DQ52590685-E6C63AAB-D30F-425F-BA39-11B2929564A2Q52630284-24C0A51A-2CBF-4778-B88D-E4764F25DA66Q52721221-349C7DCF-E8CA-46E4-B311-93716577636FQ54218762-A1E97C09-6DE6-4680-8A09-29A0BF3A58CCQ55008806-846F71A2-F630-4C22-9EAE-D9D0C0BF523BQ55425717-294BF008-0941-464F-A512-601682FA7897Q57787094-DF64C4F6-AD1D-4178-BBC2-B30D5AB6CEADQ57801734-5CD48709-FC90-41C7-A78A-38201D96D97DQ58130496-E459072C-F95D-48FC-A893-82647800257BQ58719363-B756BA43-2754-444E-B5CE-654CD59AE2D8Q58806123-4EE3F0CF-E161-43E8-B734-F6C6A7E39A88
P2860
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
HDAC Inhibition Upregulates PD ...... unotherapy with PD-1 Blockade.
@ast
HDAC Inhibition Upregulates PD ...... unotherapy with PD-1 Blockade.
@en
type
label
HDAC Inhibition Upregulates PD ...... unotherapy with PD-1 Blockade.
@ast
HDAC Inhibition Upregulates PD ...... unotherapy with PD-1 Blockade.
@en
prefLabel
HDAC Inhibition Upregulates PD ...... unotherapy with PD-1 Blockade.
@ast
HDAC Inhibition Upregulates PD ...... unotherapy with PD-1 Blockade.
@en
P2093
P2860
P1476
HDAC Inhibition Upregulates PD ...... munotherapy with PD-1 Blockade
@en
P2093
Amod Sarnaik
Andressa L Sodré
David M Woods
Eduardo M Sotomayor
Jeffrey Weber
P2860
P304
P356
10.1158/2326-6066.CIR-15-0077-T
P577
2015-08-21T00:00:00Z